Fatty liver develops when your liver accumulates more fat than it can process and export. In a healthy liver, small amounts of fat are normal, but when fat makes up more than 5% of the organ’s weight, it qualifies as steatosis, the medical term for fatty liver. Around 1.3 billion people worldwide are living with this condition, roughly 16% of the global population. Understanding how it happens starts with three overlapping processes: what you eat, how your body handles insulin, and how efficiently your liver clears fat.
How Fat Builds Up in the Liver
Your liver receives fat from two main sources. The first is fat circulating in your bloodstream after meals or released from your body’s fat stores. The second is fat your liver manufactures internally from excess sugar, a process called de novo lipogenesis, literally “new fat creation.”
When you eat more carbohydrates than your body needs for energy, your liver converts the surplus into fat. Glucose enters liver cells, gets broken down into a smaller molecule, and is shuttled into the cell’s energy factories. From there, it’s rebuilt step by step into a 16-carbon fatty acid called palmitate. Under normal conditions, the liver packages these fats into particles and ships them out into the bloodstream. Problems start when fat arrives or gets made faster than the liver can export it. The excess accumulates inside liver cells as fat droplets, and over time, those droplets grow.
Why Insulin Resistance Is Central
Insulin resistance is the single most important metabolic driver of fatty liver. When your cells stop responding normally to insulin, the consequences ripple through multiple organs, and the liver takes the brunt of it.
In healthy fat tissue, insulin acts as a brake on fat release. It tells fat cells to hold onto their stored triglycerides. When fat tissue becomes insulin resistant, that brake fails. Fat cells begin releasing a steady flood of fatty acids into the bloodstream, and much of it flows directly to the liver through the portal vein. At the same time, insulin resistance in the liver itself ramps up internal fat production. The liver keeps manufacturing new fat even when it’s already overloaded. This double hit, more fat arriving from outside and more being made inside, is what makes insulin resistance so effective at driving fat accumulation.
Visceral fat, the deep abdominal fat that wraps around your organs, is particularly problematic. Even in people who aren’t overweight, visceral adiposity and fat-tissue insulin resistance are strongly associated with triglyceride buildup in the liver.
The Role of Sugar, Especially Fructose
Not all dietary sugars affect the liver equally. Fructose is processed almost exclusively by the liver, and it bypasses a critical regulatory checkpoint that normally slows down sugar metabolism. Glucose hits a bottleneck partway through its breakdown, a rate-limiting enzyme that prevents the liver from being overwhelmed. Fructose skips right past that bottleneck, flooding the liver’s metabolic machinery with raw material for fat production.
This is why diets high in added sugars, particularly sugar-sweetened beverages, fruit juices, and processed foods with high-fructose corn syrup, are so closely linked to fatty liver. The effect isn’t limited to people who are overweight. High fructose intake can drive liver fat accumulation even in lean individuals, especially when combined with low fiber intake and refined carbohydrates.
Fatty Liver in People Who Aren’t Overweight
About 10 to 20% of people with fatty liver have a normal BMI, a pattern sometimes called “lean fatty liver.” This catches many people off guard because the condition is so strongly associated with excess weight. In lean individuals, the drivers are often a combination of genetics, hidden visceral fat, low muscle mass, and dietary patterns heavy in refined carbohydrates.
Gut health also plays a role. People with fatty liver tend to have altered gut bacteria, a condition called dysbiosis. When the gut lining becomes more permeable, bacterial products leak into the blood supply heading to the liver, triggering inflammation and accelerating fat storage. Changes in bile acid composition, also influenced by gut bacteria, further contribute to the problem. This gut-liver connection helps explain why two people with similar diets and body weights can have very different outcomes.
Genetics Can Stack the Deck
Your genes influence how efficiently your liver processes and clears fat. The most studied genetic variant is a mutation in a gene called PNPLA3. People who carry the risk version of this gene (known as the I148M variant) have trouble breaking down fat droplets inside liver cells. Normally, an enzyme works to dismantle stored triglycerides so they can be exported or burned for energy. The PNPLA3 mutation interferes with this process by trapping a helper protein that the enzyme needs, effectively locking fat inside the cell.
This variant is common in certain populations. It’s especially prevalent in people of Hispanic/Latino descent, which partially explains the higher rates of fatty liver in those communities. Several other gene variants, including TM6SF2 and MBOAT7, have similar effects, each nudging the liver’s fat-handling machinery toward accumulation rather than clearance.
From Fat to Inflammation
Simple fat accumulation in the liver is the first stage, and for many people it stays there without causing serious harm. But in a significant minority, the condition progresses to a more dangerous phase involving inflammation and cell damage. This inflammatory stage, now called MASH (metabolic dysfunction-associated steatohepatitis), is where real liver injury begins.
The transition happens through several overlapping mechanisms. Excess fat in liver cells generates oxidative stress, essentially producing harmful byproducts that damage cell membranes and proteins. Liver cells swell and “balloon,” a hallmark sign pathologists look for on biopsy. Meanwhile, the leaky gut phenomenon described earlier sends bacterial toxins into the liver, activating immune cells and triggering inflammatory cascades. These signals wake up specialized cells called stellate cells, which begin laying down scar tissue, a process called fibrosis.
The progression isn’t inevitable. Many people with simple fatty liver never develop inflammation. But for those who do, ongoing scarring can gradually replace functional liver tissue over years or decades.
Long-Term Risks and Progression
The major concern with fatty liver is its potential to progress through fibrosis toward cirrhosis, where so much scar tissue has formed that the liver can no longer function properly. Among people who reach the cirrhosis stage, the annual incidence of liver cancer is around 1.5%. In people with fatty liver who haven’t developed cirrhosis, the cancer risk is dramatically lower, roughly 0.08 per 1,000 people per year.
This means the vast majority of people with fatty liver will never develop liver cancer. The critical variable is fibrosis. Catching and addressing the condition before significant scarring develops changes the outlook entirely.
Reversibility and What Actually Helps
The encouraging reality is that fatty liver, particularly in its early stages, is reversible. Losing just 3 to 5% of your body weight is typically enough for fat to start disappearing from liver cells. To improve inflammation and scarring, a larger weight loss of around 10% is needed. For someone weighing 200 pounds, that’s 6 to 10 pounds to start clearing fat, and 20 pounds to address deeper damage.
The type of dietary change matters as much as the weight loss itself. Reducing added sugars, particularly fructose from sweetened drinks and processed foods, directly cuts off a major source of raw material for liver fat production. Increasing fiber, eating more whole foods, and building muscle mass through exercise all improve insulin sensitivity, which addresses the root metabolic driver. Regular physical activity reduces liver fat even without significant weight loss, likely by improving how muscle and fat tissue respond to insulin.
The Updated Name for Fatty Liver
You may encounter two different names for this condition. For decades, it was called NAFLD (non-alcoholic fatty liver disease), a name chosen largely because doctors didn’t yet understand the underlying biology well enough to name it more precisely. In 2023, a global initiative replaced it with MASLD (metabolic dysfunction-associated steatotic liver disease). The new name reflects what the condition actually is: a metabolic disease. It also drops the word “fatty,” which patients and providers found stigmatizing, and removes the “non-alcoholic” framing that defined the disease by what it wasn’t rather than what it was. The diagnosis now requires evidence of liver fat plus at least one metabolic risk factor, such as elevated blood sugar, high blood pressure, or abnormal cholesterol levels.